Evidence map›Paper›PMID 25232208›Full record

ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2014

Aberrant DNA methyltransferase 1 expression in clear cell renal cell carcinoma development and progression.

Ming Li, Ying Wang, Yongsheng Song, Renge Bu, Bo Yin, Xiang Fei, Qizhen Guo, Bin Wu

Abstract read
In one paragraph

Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Link between dysregulated hypoxia signaling and aberrant methylation in clear cell renal cell carcinoma?Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2017
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ming Li1 Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, China ; 2 Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA ; 3 Department of Nuclear Medicine, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Ying Wang1 Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, China ; 2 Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA ; 3 Department of Nuclear Medicine, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Yongsheng Song1 Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, China ; 2 Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA ; 3 Department of Nuclear Medicine, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Renge Bu1 Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, China ; 2 Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA ; 3 Department of Nuclear Medicine, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Bo Yin1 Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, China ; 2 Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA ; 3 Department of Nuclear Medicine, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Xiang Fei1 Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, China ; 2 Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA ; 3 Department of Nuclear Medicine, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Qizhen Guo1 Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, China ; 2 Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA ; 3 Department of Nuclear Medicine, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Bin Wu1 Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, China ; 2 Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA ; 3 Department of Nuclear Medicine, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo better understand the contribution of dysregulated DNA methyltransferase 1 (DNMT1) expression to the progression and biology of clear cell renal cell carcinoma (ccRCC).

methodsWe examined the differences in the expression of DNMT1 in 89 ccRCC and 22 normal tissue samples by immunohistochemistry. In addition, changes in cell viability, apoptosis, colony formation and invading ability of ccRCC cell lines (786-0 and Caki-1) were assessed after transfection with DNMT1 siRNA.

resultsWe found DNMT1 protein was significantly higher expressed in ccRCC than that of in no-tumor tissues (56.2% and 27.3%, respectively, P=0.018). The expression of DNMT1 was strongly associated with ccRCC tumor size, tumor pathology stage, histological grading, lymph node metastasis, vascular invasion, recurrence and prognosis. Moreover, knockdown of DNMT1 expression significantly inhibited ccRCC cell viability, induced apoptosis, decreased colony formation and invading ability.

conclusionsExpression of DNMT1 protein is increased in ccRCC tissues, and DNMT1 expression is associated with poor prognosis of patients. Experiments in vitro further showed DNMT1 played an essential role in proliferation and invasion of renal cancer cells. Moreover, targeting this enzyme could be a promising strategy for treating ccRCC, as evidenced by inhibited cell viability, increased apoptosis, decreased colony formation and invading ability.

Indexed as

Clear cell renal cell carcinoma (ccRCC)DNA methyltransferase 1 (DNMT1)immunohistochemistrysiRNA

Identifiers

PMID25232208
PMCPMC4153934
OpenAlexW2207083818

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.